Edition:
United States

Collegium Pharmaceutical Inc (COLL.OQ)

COLL.OQ on NASDAQ Stock Exchange Global Select Market

25.70USD
3:59pm EST
Change (% chg)

$-0.20 (-0.77%)
Prev Close
$25.90
Open
$25.61
Day's High
$26.37
Day's Low
$25.39
Volume
100,028
Avg. Vol
199,046
52-wk High
$26.73
52-wk Low
$7.37

Select another date:

Thu, Jan 11 2018

BRIEF-Janus Henderson Group Reports 10.1 Pct Passive Stake In Collegium Pharmaceutical

* JANUS HENDERSON GROUP PLC REPORTS 10.1 PERCENT PASSIVE STAKE IN COLLEGIUM PHARMACEUTICAL AS OF DEC 31, 2017 - SEC FILING Source text : [http://bit.ly/2mvIp5l] Further company coverage:

BRIEF-Depomed Announces Closing Of Nucynta Commercialization Agreement With Collegium Pharmaceutical

* DEPOMED ANNOUNCES CLOSING OF NUCYNTA COMMERCIALIZATION AGREEMENT WITH COLLEGIUM PHARMACEUTICAL

BRIEF-BioDelivery Sciences Reacquires Onsolis From Collegium Pharmaceutical

* BIODELIVERY SCIENCES REACQUIRES ONSOLIS® FROM COLLEGIUM PHARMACEUTICAL

BRIEF-Depomed Announces Nucynta® Commercialization Agreement With Collegium Pharmaceutical

* DEPOMED ANNOUNCES NUCYNTA® COMMERCIALIZATION AGREEMENT WITH COLLEGIUM PHARMACEUTICAL

BRIEF-Collegium To License Rights To Commercialize Nucynta Franchise

* COLLEGIUM TO LICENSE RIGHTS TO COMMERCIALIZE NUCYNTA FRANCHISE

BRIEF-Collegium reports third quarter loss of $0.45 per share

* Collegium reports third quarter financial results and provides corporate update

BRIEF-Collegium receives FDA approval for sNDA for Xtampza® ER

* Collegium receives FDA approval for sNDA for Xtampza® ER Source text for Eikon: Further company coverage:

BRIEF-Collegium notified that the FDA will not meet PDUFA goal date for SNDA for Xtampza ER

* Collegium notified that the FDA will not meet PDUFA goal date for SNDA for Xtampza® ER

Select another date: